@article{87c44b7c51324a02b07ce21342228960,
title = "Intermittent prophylactic antibiotics for bronchiectasis",
abstract = "{\textcopyright} 2019 The Cochrane Collaboration. This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the safety and efficacy of intermittent prophylactic antibiotics in the treatment of adults and children with bronchiectasis.",
keywords = "antibioticsbronchiectasis",
author = "Sally Spencer and Tim Donovan and Chalmers, {J D} and Mathioudakis, {A G} and McDonnell, {M J} and Anthony Tsang and G Pilkington",
note = "Funding Information: J.D. Chalmers: member of the EMBARC group that set research priorities in bronchiectasis. He also receives grant support from Pfizer, AstraZeneca, and GlaxoSmithKline. In addition, he is part of an innovative medicines initiative consortium that includes Novartis and Basilea Pharmaceutica. He has participated in advisory boards for Bayer HealthCare, Chiesi, and Raptor Pharmaceuticals. He has received speaker fees from Napp, AstraZeneca, BI, and Pfizer. None of these conflicts of interest are related to the work of this review and are unrelated to the topic of the review. Funding Information: This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health. Publisher Copyright: {\textcopyright} 2019 The Cochrane Collaboration.",
year = "2019",
month = jan,
day = "31",
doi = "10.1002/14651858.CD013254",
language = "English",
volume = "2019",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "The Cochrane Collaboration",
number = "1",
}